Overview
Short Course: October 22
Conference: October 25-26
In a market that is constantly adapting and adjusting to the needs of the healthcare field, real-world evidence (RWE) is increasingly becoming important for regulatory and reimbursement decision-making. RWE, in relation to the real-world data that is collected in combination with the advancement of artificial intelligence-based analytics platforms, has led to the real-time analysis of data to better understand and gain insights on disease, approaches to treatment, and how to substantiate coverage decisions. Historically used for post-market safety monitoring, RWE is now becoming integrated throughout the product development lifecycle. DIA’s Real-World Evidence Conference will explore new and innovative applications of RWE and deliver cutting-edge insights through successful use cases, case examples, and practical applications on how stakeholders are leveraging RWE to advance healthcare knowledge and decision-making.
Featured
Short Course or Primer
-
Oct 22, 2021
Short Course 1: The Evolving Landscape of Real-World Data (RWD) and the Use of Pharmacoepidemiologic Methods and Machine Learning to Generate Credible Real-World Evidence (RWE)
Learn more
Who should attend?
Professionals involved in:
- Real-World Evidence
- Real-World Data
- Epidemiology
- Policy
- Regulatory Science
- Technology development
- Data analytics
- Clinical Research
Learning objectives
At the conclusion of this activity, participants should be able to:
- Explain how RWE is being used today to inform biopharmaceutic development across product lifecycle
- Discuss “lessons learned” from current uses of RWE by regulators, and how they can be applied for other future applications of RWE
- Recognize general considerations and key features of successful RWE studies acceptable to the regulators for effective decision-making
- Identify guidance and best practices for generating fit-for-purpose RWE for payers and HTA bodies
- Define the expanding applications of RWE to support clinical trials and evidence generation
- Evaluate the future applications of RWE in drug development
- Appraise how mobile technologies, artificial intelligence, machine learning, and other technologies are being used to generate RWE
- Evaluate how patient reported outcomes, electronic health records, and other patient data is expanding the resources for RWE
Program Committee
-
Paul Test Account Wong • Associate Director, Meeting Op
Drug Information Assoc, United States -
Brian Bradbury, DrSc, MA • Vice President, Center for Observational Research
Amgen, United States -
Dorothee Bartels, PhD, MSc • Chief Digital Officer
Aetion, Germany -
Paul M. Coplan, DrSc, MBA, MSc, FISPE • VP, Medical Device Epidemiology & Real-World Data Analytics
Johnson & Johnson, United States -
Simon Dagenais, PhD, MSc • Real-World Evidence Lead, Internal Medicine
Pfizer Inc, United States -
Marni Hall, PhD, MPH • VP & GM, Global Regulatory Science and Strategy
IQVIA, United States -
James Harnett, PharmD, MS • Executive Director, Health Economics and Outcomes Research
Regeneron Pharmaceuticals, Inc. , United States -
Jingyu (Julia) Luan, PhD • Senior Director, Global Regulatory Affairs, BioPharmaceuticals R&D
AstraZeneca, United States -
David Martin, MD, MPH • Vice President, Global Head RWE
Moderna, United States -
Delphine Saragoussi, MD, MSc • Executive Director, Real-World Evidence
PPD, part of Thermo Fisher Scientific, France -
Mark Stewart, PhD • Vice President, Science Policy
Friends of Cancer Research, United States -
Sulabha Ramchandran, PhD, MS • Vice President and Head, US and Regions, Value Evidence and Outcomes
GlaxoSmithKline, United States -
Yun Lu, PhD, MS • Mathematical Statistician, Office of Biostatistics and Pharmacovigilance, CBER
FDA, United States
Contact us
Registration Questions?
Preconference Short Courses
Additional Information
Sign up to be notified when registration opens for the DIA 2022 Events
Real-World Evidence Conference Resource Kit
